Targeting cancer cells by exploiting their resistance

Trends in Molecular Medicine

Volumn 9, Issue 7, 2003, Pages 307-312

  Blagosklonny, Mikhail V ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CELL GROWTH; CELL KILLING; CELL PROTECTION; CYTOTOXICITY; DOSE RESPONSE; DRUG INDUCED DISEASE; GROWTH INHIBITION; HUMAN; MULTIDRUG RESISTANCE; REVIEW; TREATMENT PLANNING;

EID: 0042928366     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4914(03)00111-4     Document Type: Review

References (51)

1. Druker, B.J. (2002) Perspectives on the development of a molecularly targeted agent. Cancer Cell 1, 31-36
2. Sawyers, C.L. (2002) FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer Cell 1, 413-415
3. Fisher, D.E. (1994) Apoptosis in cancer therapy: crossing the threshold. Cell 78, 539-542
4. Kastan, M.B. et al. (1995) P53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev. 14, 3-15
5. Hartwel, L.H. et al. (1997) Integrating genetic approaches into the discovery of anticancer drugs. Science 278, 1064-1068
6. Kaelin, W.G. (1999) Choosing anticancer drug targets in the postgenomic era. J. Clin. Invest. 104, 1503-1506
7. Blagosklonny, M.V. (2002) Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs. Leukemia 16, 455-462
8. Gottesman, M.M. et al. (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2, 48-58
9. Yu, J.L. et al. (2002) A paradigm for therapy-induced microenvironmental changes in solid tumors leading to drug resistance. Differentiation 70, 599-609
10. Huang, Y. et al. (1997) Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia 11, 253-257
11. Chou, T.C. et al. (1998) Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. Proc. Natl. Acad. Sci. U. S. A. 95, 15798-15802
12. Reed, J.C. (2002) Apoptosis-based therapies. Nat. Rev. Drug Discov. 1, 111-121
13. Blagosklonny, M.V. (2001) Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells. Leukemia 15, 936-941
14. Kitada, S. et al. (2000) Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 96, 393-397
15. Robey, R.W. et al. (2001) Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin. Cancer Res. 7, 145-152
16. Boerner, S.A. (2001) Effect of P-glycoprotein on flavopiridol sensitivity. Br. J. Cancer 84, 1391-1396
17. Braun, J.S. et al. (1999) Neuroprotection by a caspase inhibitor in acute bacterial meningitis. Nat. Med. 5, 298-302
18. Cursio, R. et al. (1999) A caspase inhibitor fully protects rats against lethal normothermic liver ischemia by inhibition of liver apoptosis. FASEB J. 13, 253-261
19. Kawasaki, M. et al. (2000) Protection from lethal apoptosis in lipopolysaccharide-induced acute lung injury in mice by a caspase inhibitor. Am. J. Pathol. 157, 597-603
20. Hotchkiss, R.S. et al. (1999) Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc. Natl. Acad. Sci. U. S. A. 96, 14541-14546
21. Grobmyer, S.R. et al. (1999) Peptidomimetic fluoromethylketone rescues mice from lethal endotoxic shock. Mol. Med. 5, 585-594
22. Mathiak, G. et al. (2000) Caspase-1-inhibitor ac-YVAD-cmk reduces LPS-lethality in rats without affecting haematology or cytokine responses. Br. J. Pharmacol. 131, 383-386
23. Liu, W. et al. (1998) Caspase inhibitors prevent cisplatin-induced apoptosis of auditory sensory cells. Neuroreport 9, 2609-2614
24. Iwata, A. et al. (2002) The caspase inhibitor z-VAD is more effective than CD18 adhesion blockade in reducing muscle ischemia-reperfusion injury: implication for clinical trials. Blood 100, 2077-2080
25. Chen, J. et al. (2002) Caspase inhibition by Z-VAD increases the survival of grafted bone marrow cells and improves functional outcome after MCAo in rats. J. Neurol. Sci. 199, 17-24
26. Guttenplan, N. et al. (2001) Inhibition of myocardial apoptosis as a therapeutic target in cardiovascular disease prevention: focus on caspase inhibition. Heart Dis. 3, 313-318
27. Graczyk, P.P. (2002) Caspase inhibitors as anti-inflammatory and antiapoptotic agents. Prog. Med. Chem. 39, 1-72
28. Shah, M.A. and Schwartz, G. (2001) Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin. Cancer Res. 7, 2168-2181
29. Gardner, S.N. (2002) Cell cycle phase-specific chemotherapy: computational methods for guiding treatment. Cell Cycle 1, 369-374
30. Rowinsky, E.K. and Donehower, R.C. (1995) Paclitaxel (Taxol). N. Engl. J. Med. 332, 1004-1014
31. Jordan, M.A. and Wilson, L. (1998) Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr. Opin. Cell Biol. 10, 123-130
32. Stein, W. et al. (2003) Low and high concentrations of the topo II inhibitor daunorubicin in NIH3T3 cells: reversible G2/M versus irreversible G1 and S arrest. Cell Cycle 2, 134-142
33. Blagosklonny, M.V. (1999) Drug-resistance enables selective killing of resistant leukemia cells: exploiting of drug resistance instead of reversal. Leukemia 13, 2031-2035
34. Vogelstein, B. et al. (2000) Surfing the p53 network. Nature 408, 307-310
35. Bunz, F. et al. (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282, 1497-1501
36. Bunz, F. et al. (1999) Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 104, 263-269
37. Blagosklonny, M.V. et al. (2000) Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs. J. Clin. Invest. 105, 533-539
38. Blagosklonny, M.V. (2002) Sequential activation and inactivation of G2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs. Oncogene 21, 6249-6254
39. Chene, P. (2003) Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat. Rev. Cancer 3, 102-109
40. Bishop, P.C. et al. (2002) Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family. Oncogene 21, 119-127
41. Blagosklonny, M.V. et al. (2000) Loss of cell cycle control allows selective microtubule drug-induced Bcl-2 phosphorylation and cytotoxicity in highly autonomous cancer cells. Cancer Res. 60, 3425-3428
42. WAF1/CIP1 and p53 and protects p21-sensitive cells from paclitaxel. Cancer Biol. Ther. 1, 420-425
43. Hanahan, D. and Weinberg, R.A. (2000) The hallmarks of cancer. Cell 100, 57-70
44. Pardee, A.B. and James, L.J. (1975) Selective killing of transformed baby hamster kidney (BHK) cells. Proc. Natl. Acad. Sci. U. S. A. 72, 4994-4998
45. Darzynkiewicz, Z. (1995) Apoptosis in antitumor strategies - modulation of cell-cycle or differentiation. J. Cell. Biochem. 58, 151-159
46. Blagosklonny, M.V. and Pardee, A.B. (2001) Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res. 61, 4301-4305
47. Pardee, A. (2002) Role reversal for anticancer agents. Cancer Biol. Ther. 1, 426-427
48. Du, L. et al. (2001) Selective protection of mitogenically stimulated human lymphocytes but not leukemic cells from cytosine arabinoside-induced apoptosis by LY294002, a phosphoinositol-3 kinase inhibitor. Int. J. Oncol. 19, 811-819
49. Blagosklonny, M.V. and Darzynkiewicz, Z. (2002) Cyclotherapy: protection of normal cells and unshielding of cancer cells. Cell Cycle 1, 375-382
50. Blagosklonny, M.V. (2003) A new science-business paradigm in anticancer drug development. Trends Biotechnol 21, 103-106
51. Blagosklonny, M.V. (2002) Oncogenic resistance to growth-limiting conditions. Nat. Rev. Cancer 2, 221-225